LYEL PEER ANALYSIS

Lyell Immunopharma Inc — metric-by-metric comparison with peers and the industry median

LYELLyell Immunopharma Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

LYELIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	LYEL	MSB	RTALB	TLX	Ind. Median
P/E	—	—	4.89	—	17.81
P/B	1.12	—	0.61●	6.56	3.49
EV/EBITDA	—	—	74.61●	123.31	14.92
P/S	9,907.71	31.91	6.67	3.34●	10.89

Financial Health
Metric	LYEL	MSB	RTALB	TLX	Ind. Median
Current Ratio	7.23●	—	1.21	1.43	5.90
Debt/Equity	17.9%	—	1.2%●	112.3%	10.9%
NetDebt/EBITDA	0.86●	—	0.90	13.13	1.15

Profitability
Metric	LYEL	MSB	RTALB	TLX	Ind. Median
Net Margin	-794,858.1%	-115.3%	136.3%●	-0.9%	-125.7%
ROE	-80.8%	-11.3%	15.1%●	-1.8%	-47.5%
ROA	-63.1%	-8.6%	13.1%●	-0.7%	-35.8%
EBITDA Margin	-770,932.3%	-76.6%	9.0%●	3.0%	-105.8%

Growth + Dividend
Metric	LYEL	MSB	RTALB	TLX	Ind. Median
Rev. Growth	-52.3%	410.4%●	24.0%	56.3%	5.1%
NI Growth	—	—	134.0%	—	12.1%
Div. Yield	—	0.0%●	0.0%●	—	0.2%
Payout	—	0.0%	0.0%	—	0.0%

Valuation
Metric	LYEL	OABI	ZNTL	MGNX	TRDA	ENTA	Ind. Median
P/E	—	—	—	—	—	—	17.81
P/B	1.12●	1.18	1.82	13.68	1.16	2.66	3.49
EV/EBITDA	—	—	—	—	—	—	14.92
P/S	9,907.71	10.70	—	1.85●	54.90	4.48	10.89

Financial Health
Metric	LYEL	OABI	ZNTL	MGNX	TRDA	ENTA	Ind. Median
Current Ratio	7.23	4.80	6.19	1.90	13.90●	3.84	5.90
Debt/Equity	17.9%	7.5%●	21.2%	172.2%	18.4%	160.1%	10.9%
NetDebt/EBITDA	0.86	0.87	1.32	2.32	1.24	-0.49●	1.15

Profitability
Metric	LYEL	OABI	ZNTL	MGNX	TRDA	ENTA	Ind. Median
Net Margin	-794,858.1%	-187.7%	—	-44.8%●	-2,895.1%	-89.6%	-125.7%
ROE	-80.8%	-20.2%●	-51.9%	-140.3%	-48.3%	-59.0%	-47.5%
ROA	-63.1%	-18.1%●	-39.0%	-31.8%	-40.4%	-19.4%	-35.8%
EBITDA Margin	-770,932.3%	-117.0%	—	-32.2%●	-2,873.3%	-67.3%	-105.8%

Growth + Dividend
Metric	LYEL	OABI	ZNTL	MGNX	TRDA	ENTA	Ind. Median
Rev. Growth	-52.3%	8.1%●	-100.0%	3.1%	-96.7%	7.4%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on LYEL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.